Prognostic value of serum lactic dehydrogenase (S‐LDH) in multiple myeloma

Publisher Website
Google Scholar
Abstract
Serum lactic dehydrogenase (S-LDH) was analysed at diagnosis in ninety-three patients with multiple myeloma. The patients were then followed up after a mean observation period of 30 months (SD 29). Serum lactic dehydrogenase was elevated in twenty-seven out of ninety-three patients and found to correlate with the serum concentrations of .beta.2-microglobulin, creatinine, and thymidine kinase. In discriminant analysis of pretreatment S-LDH levels in relation to survival, the best discrimination level was 7.0 .mu.kat l-1. Patients with values below 7 .mu.kat l-1 had a median survival time of 45 months compared to 14 months for those with levels above 7 .mu.kat l-1 (P < 0.001). Serum lactic dehydrogenase at diagnosis, thus, has prognostic information in multiple myeloma.